PeterMD Review

What PeterMD charges

• Sermorelin: $211.65/mo — the price of a 4-Week Supply, in the seller's own words — four weeks is not a calendar month. The same page lists a 12-Week Supply at $585.00 against a stated regular price of $634.95, and this site makes no claim about what that regular price was ever charged at.
• NAD+: $369/mo — the price of two vials the page calls an "8-10 Week Supply" — a range, so nothing on the page supports a per-month figure for this product

The only per-compound exclusion list compared here

The sermorelin page header says the product is not available in two named states. The NAD+ page header, in the same position on the same site, names three.

Louisiana is excluded for NAD+ and not for sermorelin. That is a real difference, published by the seller, and it is the kind of detail almost every site in this market leaves to an intake.

This roster records one state footprint per seller, and one list cannot say two things. So no positive list is recorded here, and both sentences are reproduced above instead.

Twenty-one of the forty-five sellers here publish a state list of some kind. This seller publishes exclusions rather than a list, which answers a narrower question but answers it on the page.

Weeks, not months, and one range

The sermorelin figure buys a four-week supply, in the page's own words. Four weeks is not a calendar month, and thirty of the two hundred and two figures compared here state their period in weeks.

The NAD+ figure buys two vials the page calls an eight-to-ten-week supply. That is a range, so nothing on the page supports a per-month figure for it, and none is invented here.

The sermorelin page also lists a twelve-week supply at a lower price than the four-week rate multiplied out, shown against a stated regular price and a saving.

A reduction is only as meaningful as the price it is measured against, and the page says nothing about when or for how long that regular price was charged.

A large claim, and no company behind it

The site describes itself as the largest online healthcare clinic in North America and links a certification checker for its own domain.

Neither the home page, the terms, either privacy policy nor the about page names the company operating the site. The about page names people and mentions an unrelated company belonging to one of them.

The terms do name a governing law, Oklahoma, and say the arbitration agreement is governed by the Federal Arbitration Act. That is more than several sellers here publish and less than a company name.

Ten of the forty-five sellers compared here name the facility that fills an order; this is one of the thirty-five that do not.

Two compounds inside a much larger catalog

Sermorelin and NAD+ are the compounds this site tracks here. NAD+ also appears in a capsule at a separate page, which is a different product from the injection priced on this row.

The rest of the catalog is hormone therapy, weight-loss medication, sexual-health medication, hair loss and thyroid products. None of those is compared on this site.

Neither compound is an FDA-approved finished drug in the form sold here.

One figure appears repeatedly in this site's markup and is not published: an add-on offer that sits inside a panel a reader is never shown. It is excluded from this row.

How we verified this

• Read both product pages as rendered text and took the figures, the supply lengths and the exclusion sentences from the page a buyer sees.
• Checked the computed visibility of every dollar figure on both pages and excluded a repeated add-on figure that sits inside a panel no control on the page opens.
• Took both product addresses from the site's own links after an indexed product address turned out not to exist.
• Recorded the two exclusion sentences separately rather than merging them, because they name different states.
• Declined to record a positive state list, because building one would mean subtracting the seller's exclusions from fifty and publishing a list the seller never wrote.
• Read the home page, the terms, both privacy policies and the about page for an operating company and an address, and confirmed neither appears.
• Took the governing law from the numbered clause in the terms rather than from a summary.
• Probed the host with a nonsense path in the same pass and confirmed it answers with its own not-found page.
• Searched the published federal warning-letter record for the brand across the years that record covers. The rows returned name other companies, and none is this one. That record does not include untitled letters.
• Re-counted the state-list and pharmacy-naming claims against the current roster rather than reusing an earlier figure.